These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Development of Mycoplasma pneumoniae biofilms in vitro and the limited role of motility. Feng M; Schaff AC; Cuadra Aruguete SA; Riggs HE; Distelhorst SL; Balish MF Int J Med Microbiol; 2018 Apr; 308(3):324-334. PubMed ID: 29426802 [TBL] [Abstract][Full Text] [Related]
4. Mycoplasma pneumoniae Community Acquired Respiratory Distress Syndrome toxin expression reveals growth phase and infection-dependent regulation. Kannan TR; Musatovova O; Balasubramanian S; Cagle M; Jordan JL; Krunkosky TM; Davis A; Hardy RD; Baseman JB Mol Microbiol; 2010 Jun; 76(5):1127-41. PubMed ID: 20199607 [TBL] [Abstract][Full Text] [Related]
13. The LuxS/AI-2 Quorum-Sensing System of Yadav MK; Vidal JE; Go YY; Kim SH; Chae SW; Song JJ Front Cell Infect Microbiol; 2018; 8():138. PubMed ID: 29780750 [No Abstract] [Full Text] [Related]
14. Streptococcus pneumoniae biofilm formation and dispersion during colonization and disease. Chao Y; Marks LR; Pettigrew MM; Hakansson AP Front Cell Infect Microbiol; 2014; 4():194. PubMed ID: 25629011 [TBL] [Abstract][Full Text] [Related]
15. Pathogenesis of Mycoplasma pneumoniae: An update. Chaudhry R; Ghosh A; Chandolia A Indian J Med Microbiol; 2016; 34(1):7-16. PubMed ID: 26776112 [TBL] [Abstract][Full Text] [Related]
16. The effects of magainin 2-derived and rationally designed antimicrobial peptides on Mycoplasma pneumoniae. Hayashi K; Misawa T; Goto C; Demizu Y; Hara-Kudo Y; Kikuchi Y PLoS One; 2022; 17(1):e0261893. PubMed ID: 35073323 [TBL] [Abstract][Full Text] [Related]
17. Characterization of biofilm matrix, degradation by DNase treatment and evidence of capsule downregulation in Streptococcus pneumoniae clinical isolates. Hall-Stoodley L; Nistico L; Sambanthamoorthy K; Dice B; Nguyen D; Mershon WJ; Johnson C; Hu FZ; Stoodley P; Ehrlich GD; Post JC BMC Microbiol; 2008 Oct; 8():173. PubMed ID: 18842140 [TBL] [Abstract][Full Text] [Related]
18. Synthesis and distribution of CARDS toxin during Mycoplasma pneumoniae infection in a murine model. Kannan TR; Coalson JJ; Cagle M; Musatovova O; Hardy RD; Baseman JB J Infect Dis; 2011 Nov; 204(10):1596-604. PubMed ID: 21957154 [TBL] [Abstract][Full Text] [Related]
19. Type 1 and type 2 strains of Mycoplasma pneumoniae form different biofilms. Simmons WL; Daubenspeck JM; Osborne JD; Balish MF; Waites KB; Dybvig K Microbiology (Reading); 2013 Apr; 159(Pt 4):737-747. PubMed ID: 23412845 [TBL] [Abstract][Full Text] [Related]
20. Vaccine using community-acquired respiratory distress syndrome toxin as an antigen against Mycoplasma pneumoniae in mice. Yoshikawa E; Tamiya S; Inoue Y; Suzuki K; Yoshioka Y Biochem Biophys Res Commun; 2022 Feb; 594():81-87. PubMed ID: 35078111 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]